By RTT News, November 19, 2014, 09:19:00 AM EDT
(RTTNews.com) - Bio Blast Pharma Ltd. ( ORPN ) announced it has been granted Orphan Drug Designation by the U.S. FDA for Cabaletta for the treatment of Spinocerebellar Ataxia Type 3 (known as SCA3 and Machado Joseph disease). This is the second indication for which Bio Blast's Cabaletta has received such designation.
Cabaletta is a chemical chaperone that protects against pathological processes in cells. The company noted that Cabaletta has demonstrated efficacy in preclinical cells and animal models of SCA3 and other PolyA/PolyQ diseases, including Occulopharyngeal Muscular Dystrophy and Spino bulbar cerebellar ataxia. Bio Blast plans to make clinical progress in each of these indications in 2015.
For comments and feedback: contact editorial@rttnews.com
See the original post:
Bio Blast: Cabaletta Gets Orphan Drug Designation For Treatment Of SCA3 Disease